(2021) Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study. New Microbes and New Infections. p. 4.
Text
Rifampicin resistance in Mycobacterium tuberculosis in Iran a two-centre study.pdf Download (177kB) |
Abstract
Multidrug-resistant tuberculosis remains a challenge. In this study, we investigated the incidence of rifampicin (RIF) resistance in Mycobacterium tuberculosis in a large number of pulmonary specimens. A two-center study in Tehran, the capital of Iran, was performed with 6624 pulmonary samples of patients with tuberculosis (TB) who were subjected to detection of RIF-resistant TB by GeneXpert MTB/RIF assay between May 2014 and July 2018. Conventional drug susceptibility testing was performed to confirm the results. Xpert MTB/RIF identified a total of 96 positives for M. tuberculosis, of which 5 (5.3) samples were found to be RIF-resistant TB. All RIF resistant and sensitive isolates detected by GeneXpert were phenotypically confirmed by drug susceptibility testing. These results indicated that the Xpert MTB/RIF test can be used as a rapid diagnostic method and can potentially decrease the morbidity associated with diagnostic delay and mistreatment. (c) 2021 The Authors. Published by Elsevier Ltd.
Item Type: | Article |
---|---|
Keywords: | Drug resistance rifampicin tuberculosis Xpert MTB RIF genexpert mtb/rif assay xpert mtb/rif drug-resistance high-rates mdr-tb diagnosis pulmonary Infectious Diseases Microbiology |
Page Range: | p. 4 |
Journal or Publication Title: | New Microbes and New Infections |
Journal Index: | ISI |
Volume: | 42 |
Identification Number: | https://doi.org/10.1016/j.nmni.2021.100909 |
Depositing User: | مهندس مهدی شریفی |
URI: | http://eprints.bmsu.ac.ir/id/eprint/9730 |
Actions (login required)
View Item |